Stockscreener 앱 받기
5.15
0.98%
0.05
시간 외 거래:
5.09
-0.06
-1.17%
전일 마감가:
$5.10
열려 있는:
$5.14
하루 거래량:
1.01M
Relative Volume:
0.89
시가총액:
$377.22M
수익:
$31,000
순이익/손실:
$-38.18M
주가수익비율:
-7.3466
EPS:
-0.701
순현금흐름:
$-38.90M
1주 성능:
+4.04%
1개월 성능:
+10.28%
6개월 성능:
-13.81%
1년 성능:
+4.04%
1일 변동 폭
$5.04
$5.2025
1주일 범위
$4.76
$5.2025
52주 변동 폭
$4.3384
$7.25
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.15 | 373.56M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs - Traders Union
Aug Analyst Calls: Should I hold or sell Candel Therapeutics Inc now2026 Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat
Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026 - Traders Union
Dow Update: Is Candel Therapeutics Inc affected by consumer sentimentMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Winners Losers: Can Candel Therapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance UK
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan
Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan
CADL Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m - simplywall.st
Candel gains on additional mid-stage trial data for lead asset - MSN
Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Barchart.com
Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan
Buy Signal: Should I hold or sell Candel Therapeutics Inc nowQuarterly Investment Review & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data By Investing.com - Investing.com Australia
Will Candel Therapeutics Inc outperform small cap indexesWall Street Watch & Weekly High Conviction Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data - Investing.com
Candel Therapeutics prices $100M public offering at $5.45 per share - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Market movers: Uber, Getty Images, Candel Therapeutics... - Proactive Investors
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news
Candel reports extended survival data for lung cancer therapy - Investing.com
Candel Therapeutics Inc extended survival tail observed in trial of aglatimagene besadenovec - marketscreener.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Bitget
Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec - TradingView
Candel Therapeutics Reports Extended Survival Tail Observed - GlobeNewswire
Aug Drivers: Is Candel Therapeutics Inc stock forming a triangle pattern2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
FY2030 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - The Globe and Mail
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
CADL: Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028 - TradingView
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):